Tag Archives: GlycoMimetics

May, 2017

June, 2016

  • 13 June

    FDA Grants Fast Track Status to GlycoMimetics’ AML Drug

    ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and elderly patients aged 60 years or older with AML. …